Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. Issue 13 (April 2019)

• Record Type: Journal Article
• Authors: Elson, Elizabeth Claire; Mermis, Joel; Polineni, Deepika; Oermann, Christopher M
• Is Part Of: Clinical medicine insights. Issue 13(2019)
• Publication Date: 2019-04
• Subjects: Cystic fibrosis -- aztreonam lysine -- inhalation -- Pseudomonas; Cardiovascular system -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Blood Circulation; Respiration; Lung Diseases; Cardiovascular system -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; Periodicals; 616.1005
• DOI: 10.1177/1179548419842822
• Languages: English
• ISSNs: 1179-5484

Abstract

Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in improvements in quality of life and life expectancy. Aztreonam lysine for inhalation (AZLI) solution was initially approved to improve respiratory symptoms in CF patients with Pseudomonas aeruginosa (PA) in 2010 by the Food and Drug Administration. Since then, research broadening labeling and clinical application has been developed. In this review, we analyze published and ongoing research regarding AZLI therapy in CF. A search of the Cochrane Database of Systematic Reviews and the PubMed and ClinicalTrials.gov databases was conducted to identify publications about AZLI. Three pre-approval studies were identified and assessed. Two are Phase 3, placebo-controlled trials, assessing a variety of safety and efficacy endpoints, leading to FDA approval. The third is an open-label extension of the two previous trials. An additional seven post-approval, completed trials were identified and are included in this review. They represent a variety of study designs including safety and efficacy in patients with mild lung disease and young patients, an active comparator trial vs inhaled tobramycin, an eradication study, a study among patients with Burkholderia cepacia, and a study assessing continuous alternating antibiotic therapy. Finally, five ongoing clinical trials are discussed. Overall, studies demonstrated that inhaled aztreonam is a safe and effective antimicrobial treatment for the eradication of newly acquired P. aeruginosa and long-term suppressive therapy of chronic endobronchial infection among people with cystic fibrosis.